The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

However, some research suggests that poor sleep could raise your risk of Alzheimer’s. A study published in November found ...

According to recent research published in ‘Alzheimer's & Dementia’, delays in entering the rapid eye movement (REM) sleep ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Dr Eric Berg DC has shared 'hidden dangers' and numerous health risks of the problem that affects many at night ...

According to the Alzheimer’s Association ( there are currently 6.5 million people with Alzheimer’s disease. An estimated 6.9 ...

Gavin Patterson joins Alzheimer's Research UK as chair. The former President and Chief Revenue Officer of Salesforce and CEO ...